Metabotropic Glutamate Receptor 5: A Potential Target for Neuropathic Pain Treatment

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2024 Oct 16

PMID 39411936

Authors

Chalton Manengu

Chun-Hao Zhu

Guo-Dong Zhang

Miao-Miao Tian

Xiao-Bing Lan

Li-Jun Tao

Lin Ma

Yue Liu

Jian-Qiang Yu

Ning Liu

Affiliations

Soon will be listed here.

Abstract

Neuropathic pain, a multifaceted and incapacitating disorder, impacts a significant number of individuals globally. Despite thorough investigation, the development of efficacious remedies for neuropathic pain continues to be a formidable task. Recent research has revealed the potential of metabotropic glutamate receptor 5 (mGlu5) as a target for managing neuropathic pain. mGlu5 is a receptor present in the central nervous system that has a vital function in regulating synaptic transmission and the excitability of neurons. This article seeks to investigate the importance of mGlu5 in neuropathic pain pathways, analyze the pharmacological approach of targeting mGlu5 for neuropathic pain treatment, and review the negative allosteric mGlu5 modulators used to target mGlu5. By comprehending the role of mGlu5 in neuropathic pain, we can discover innovative treatment approaches to ease the distress endured by persons afflicted with this incapacitating ailment.

References

Bouhassira D . Neuropathic pain: Definition, assessment and epidemiology. Rev Neurol (Paris). 2018; 175(1-2):16-25. DOI: 10.1016/j.neurol.2018.09.016. View

Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson A, Yarnitsky D . Neuropathic pain. Nat Rev Dis Primers. 2017; 3:17002. PMC: 5371025. DOI: 10.1038/nrdp.2017.2. View

Dupoiron D, Brill S, Eeltink C, Barragan B, Bell D, Petersen G . Diagnosis, management and impact on patients' lives of cancer-related neuropathic pain (CRNP): A European survey. Eur J Cancer Care (Engl). 2022; 31(6):e13728. PMC: 9788326. DOI: 10.1111/ecc.13728. View

Irving G . Contemporary assessment and management of neuropathic pain. Neurology. 2005; 64(12 Suppl 3):S21-7. DOI: 10.1212/wnl.64.12_suppl_3.s21. View

Aley K, Reichling D, Levine J . Vincristine hyperalgesia in the rat: a model of painful vincristine neuropathy in humans. Neuroscience. 1996; 73(1):259-65. DOI: 10.1016/0306-4522(96)00020-6. View

Finnerup N, Kuner R, Jensen T . Neuropathic Pain: From Mechanisms to Treatment. Physiol Rev. 2020; 101(1):259-301. DOI: 10.1152/physrev.00045.2019. View

Chu X, Song X, Li Q, Li Y, He F, Gu X . Basic mechanisms of peripheral nerve injury and treatment via electrical stimulation. Neural Regen Res. 2022; 17(10):2185-2193. PMC: 9083151. DOI: 10.4103/1673-5374.335823. View

Boyd A, Byrne S, Middleton R, Banati R, Liu G . Control of Neuroinflammation through Radiation-Induced Microglial Changes. Cells. 2021; 10(9). PMC: 8468704. DOI: 10.3390/cells10092381. View

Inoue K, Tsuda M . Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential. Nat Rev Neurosci. 2018; 19(3):138-152. DOI: 10.1038/nrn.2018.2. View

10.

Navarro X . Chapter 27: Neural plasticity after nerve injury and regeneration. Int Rev Neurobiol. 2009; 87:483-505. DOI: 10.1016/S0074-7742(09)87027-X. View

11.

Meacham K, Shepherd A, Mohapatra D, Haroutounian S . Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr Pain Headache Rep. 2017; 21(6):28. DOI: 10.1007/s11916-017-0629-5. View

12.

Sharma A, Behl T, Sharma L, Shah O, Yadav S, Sachdeva M . Exploring the molecular pathways and therapeutic implications of angiogenesis in neuropathic pain. Biomed Pharmacother. 2023; 162:114693. DOI: 10.1016/j.biopha.2023.114693. View

13.

Novakovic S, Tzoumaka E, McGivern J, Haraguchi M, Sangameswaran L, Gogas K . Distribution of the tetrodotoxin-resistant sodium channel PN3 in rat sensory neurons in normal and neuropathic conditions. J Neurosci. 1998; 18(6):2174-87. PMC: 6792911. View

14.

Latremoliere A, Woolf C . Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009; 10(9):895-926. PMC: 2750819. DOI: 10.1016/j.jpain.2009.06.012. View

15.

Nijs J, Van Houdenhove B, Oostendorp R . Recognition of central sensitization in patients with musculoskeletal pain: Application of pain neurophysiology in manual therapy practice. Man Ther. 2009; 15(2):135-41. DOI: 10.1016/j.math.2009.12.001. View

16.

Meeus M, Nijs J, Van de Wauwer N, Toeback L, Truijen S . Diffuse noxious inhibitory control is delayed in chronic fatigue syndrome: an experimental study. Pain. 2008; 139(2):439-448. DOI: 10.1016/j.pain.2008.05.018. View

17.

Meeus M, Nijs J . Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol. 2006; 26(4):465-73. PMC: 1820749. DOI: 10.1007/s10067-006-0433-9. View

18.

Fields H, ROWBOTHAM M, Baron R . Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol Dis. 1998; 5(4):209-27. DOI: 10.1006/nbdi.1998.0204. View

19.

Woolf C, Shortland P, Coggeshall R . Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature. 1992; 355(6355):75-8. DOI: 10.1038/355075a0. View

20.

Gracely R, Lynch S, Bennett G . Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain. 1992; 51(2):175-194. DOI: 10.1016/0304-3959(92)90259-E. View